Fulgent Genetics Reports Record Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Fulgent Genetics, Inc. (FLGT) Tops Q4 EPS by $2.15, Revenues Rise 3400%; Raises Outlook
March 4, 2021 4:15 PM ESTFulgent Genetics, Inc. (NASDAQ: FLGT) reported Q4 EPS of $6.20, $2.15 better than the analyst estimate of $4.05. Revenue for the quarter came in at $295 million versus the consensus estimate of $199.44 million.
GUIDANCE:
Fulgent Genetics, Inc. sees FY2021 EPS of $12.50, versus the consensus of $11.55. Fulgent Genetics, Inc. sees FY2021 revenue of $800 million, versus the consensus of $600.24 million.
Ming Hsieh, Chairman and Chief Executive Officer, said, Our record fourth quarter results capped off a transformational year for Fulgent Genetics. While we did not envision 2020 to unfold in... More
